Rituximab Effective for Lupus-Associated Cytopenia

This article originally appeared here.
Share this content:
Rituximab Effective for Lupus-Associated Cytopenia
Rituximab Effective for Lupus-Associated Cytopenia

WEDNESDAY, Dec. 27, 2017 (HealthDay News) -- Rituximab treatment seems effective for systemic lupus erythematosus (SLE)-associated immune cytopenias, with an overall initial response rate of 86 percent, according to a study published online Dec. 16 in the American Journal of Hematology.

Alexandra Serris, M.D., from the Université Paris-Est Créteil, and colleagues conducted a retrospective cohort study involving 71 patients aged ≥18 years with a definite diagnosis of SLE treated with rituximab specifically for SLE-associated immune cytopenia.

The researchers found that the median duration of SLE at the time of first rituximab administration was 6.1 years. The reason for using rituximab was immune thrombocytopenia, autoimmune hemolytic anemia, Evans syndrome, and pure red cell aplasia for 44, 16, 10, and one patient, respectively. Patients had a mean of 3.1±1.3 treatments before receiving rituximab, including corticosteroids and hydroxychloroquine (100 and 88.5 percent, respectively). The overall initial response rate to rituximab was 86 percent, with a complete response for 60.5 percent. Of the 61 initial responders, 24 relapsed; rituximab re-treatment was successful for 16 of 18. Three patients had severe infections after rituximab, with no fatal outcomes. There were no cases of rituximab-induced neutropenia.

"In conclusion, rituximab seems effective and relatively safe for treating SLE-associated immune cytopenias," the authors write.

Several authors disclosed financial ties to Roche.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »